Serum CA-125 measurements > 65 U/mL: Clinical value

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 42, Issue 10, 1997, Pages 617-624

  Eltabbakh, Gamal H ^a   Belinson, Jerome L ^b   Kennedy, Alexander W ^b   Gupta, Manjula ^b   Webster, Kenneth ^b   Blumenson, Leslie E ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CA 125 antigen; Ovarian neoplasm

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOMETRIOSIS; FEMALE; GYNECOLOGIC CANCER; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MENOPAUSE; PHYSICAL EXAMINATION; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; RISK; SERUM;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; ENDOMETRIOSIS; FEMALE; GENITAL NEOPLASMS, FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POSTMENOPAUSE; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 0030848818     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887
2. Di-Xia C, Schwartz PE, Xinguo L, et al: Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988; 72:23-27
3. Maggino T, Gadducci A, D'Addario V, et al: Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117-123
4. Niloff JM: Tumor markers. In Principles and Practice of Gynecology Oncology. Edited by WJ Hoskins, CA Perez, RC Young. Philadelphia, JB Lippincott, 1992, pp 137-150
5. Klug TL, Bast RC Jr, Niloff JM, et al: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 1984;44:1048-1053
6. Cancer Committee of the International Federation of Gynecology and Obstetrics: Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 1986;25:383-385
7. Zurawski VR, Sjovall K, Schoenfeld DA, et al: Prospective evaluation of serum CA 125 levels in a normal population, phase I: The specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 1990;36:299-305
8. Grover S, Quinn MA, Weideman P, et al: Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 1992;79:511-514
9. Niloff JM, Knapp RC, Schaetzl EM, et al: CA 125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703-708
10. Zurawski VR, Broerick SF, Pickens P, et al: Serum CA 125 levels in a group of nonhospitalized women: Relevance for the early detection of ovarian cancer. Obstet Gynecol 1987;69:606-611
11. Malkasian GD, Knapp RC, Lavin PT, et al: Pre-operative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-346
12. Haga Y, Sakamoto K, Egami H, et al: Clinical significance of serum CA 125 values in patients with cancers of the digestive system. Am J Med Sci 1986;292:30-34
13. Canney PA, Moore M, Wilkinson PM, et al: Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumor marker. Br J Cancer 1984;50:765-769
14. Niloff JA, Klug TL, Schaetzl E, et al: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984;148:1057-1058
15. Duk JM, Aalders JG, Fleuren GJ, et al: CA 125: A useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:1097-1102
16. Pastner B, Mann WJ, Cohen H, et al: Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 1988; 158:399-102
17. Scambia G, Gadducci A, Panici PB, et al: Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol 1994;54:292-297
18. Fedele L, Vercellini P, Arcaini L, et al: CA 125 in serum, peritoneal fluid, active lesions and endometrium of patients with endometriosis. Am J Obstet Gynecol 1988;158:166-170
19. Bischof P, Galfetti MA, Seydoux J, et al: Peripheral CA 125 levels in patients with uterine fibroids. Hum Reprod 1992;7:35-38
20. Paavonen J, Miettinen A, Heinonen PK, et al: Serum CA-125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol 1989;96:574-579
21. Mezger J, Wilmanns W, Lamerz R: Elevated serum CA-125 levels in patients with benign ascitic or pleural effusions. Tumor Biol 1988;9:47-52
22. Koninckx PR, Rittinen L, Seppala M, et al: CA 125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis. Fertil Steril 1992;57:523-530
23. Tholander B, Taube A, Lindgren A, et al: Pretreatment serum levels of CA-125, carcinoembrynic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: Influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990;39:26-33
24. Molina R, Ojeda B, Filella X, et al: A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumor Biol 1992;13:278-286
25. Zanaboni F, Vergadoro F, Presti M, et al: Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma. Gynecol Oncol 1987;28:61-67
26. Piver MS: Specialized surgery in ovarian cancer. Eur J Cancer Clin Oncol 1987;23:123-125
27. Eisenkop SM, Spirtos NM, Montag TW, et al: The impact of subspeciality training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-209